<i>Hedychium spicatum</i> Improves Cognitive Function and Reduces Anxiety in PTZ-Kindled Rats through Non-Cholinergic Mechanisms
Aim: Hedychium spicatum (HS) is known to possess antioxidant and neuroprotective properties. The present study aimed to evaluate the protective effects of HS against pentylenetetrazole (PTZ) induced cognitive deficits in rats. Materials and Methods: Male Wistar rats (n = 48) were randomly divided into six groups (n = 8): normal control (saline), PTZ control (35 mg/kg, i.p.), PTZ + vehicle (1% CMC, p.o.), PTZ + escitalopram (5 mg/kg, p.o.), PTZ + HS (200 mg/kg, p.o.), and PTZ + HS (400 mg/kg, p.o.). Kindling was induced by administering PTZ (35 mg/kg, i.p.) every 48 h for 20 days. Treatment with HS and escitalopram was initiated on day 6 and continued for 15 days. Behavioural evaluations included the T-maze and novel object recognition tests, the elevated plus maze, and the open field test for exploratory and locomotor activity. After behavioural assessments, brain tissues were collected for biochemical estimation of acetylcholinesterase activity. Results: Rats treated with HS showed significant improvements in memory performance in the T-maze and novel object recognition tests, with the higher dose (400 mg/kg) producing effects comparable to those of escitalopram. HS also significantly reduced anxiety-like behaviour in the elevated plus maze. Exploratory and locomotor activities in the open field test remained largely unaffected, indicating the absence of nonspecific stimulatory or sedative effects. However, acetylcholinesterase activity in brain tissue did not change significantly following HS treatment. Conclusion: HS attenuated PTZ-induced cognitive deficits and anxiety-like behaviour in rats, suggesting that its beneficial effects may involve mechanisms other than cholinergic modulation. Major Findings: Hedychium spicatum markedly attenuated PTZ-induced cognitive deficits and anxiety-like behaviour in rats, particularly at the 400 mg/kg dose, which demonstrated efficacy comparable to escitalopram. The absence of significant changes in brain acet